1 NAME OF THE MEDICINE
Pantoprazole (as sodium sesquihydrate)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each SALPRAZ 20mg enteric coated tablet contains 22.56 mg pantoprazole sodium sesquihydrate equivalent to 20mg of pantoprazole.

Each SALPRAZ 40mg enteric coated tablet contains 45.12 mg of pantoprazole sodium sesquihydrate equivalent to 40mg of pantoprazole.

Salpraz also contains traces of soya bean product.

For the full list of excipients, see Section 6.1 List of excipients.

3 PHARMACEUTICAL FORM
SALPRAZ 20 mg enteric-coated tablets are yellow to light yellow, oval shaped, biconvex enteric coated tablets plain on both sides.

SALPRAZ 40 mg enteric-coated tablets are yellow to light yellow, oval shaped, biconvex enteric coated tablets plain on both sides.

4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS

Adults
1. Symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion:
   - duodenal ulcer
   - gastric ulcer
   - gastro-oesophageal reflux disease (GORD):
     i. symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD
     ii. reflux oesophagitis
   - gastrointestinal lesions refractory to H2 blockers
   - Zollinger-Ellison Syndrome

Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.

2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.

3. For eradication of Helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics:
   - clarithromycin and amoxicillin or
   - clarithromycin and metronidazole or
   - amoxicillin and metronidazole
is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see section 4.2 Dose and Method of Administration).

4. Pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of *Helicobacter pylori* associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism.

5. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.

**Children Aged from 5 to 17 Years**

Gastrooesophageal Reflux Disease (GORD)

- Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD
- Reflux oesophagitis

The treatment duration should not exceed 8 weeks.

### 4.2 DOSE AND METHOD OF ADMINISTRATION

SALPRAZ is available as a tablet formulation. SALPRAZ tablets should not be chewed or crushed but swallowed whole with a little water.

Patients who have difficulty swallowing tablets may use pantoprazole granules (available from other brands).

In *H. pylori* positive patients with gastric and duodenal ulcers, eradication of this microorganism by combination therapy should be achieved. One of the following combinations of pantoprazole with antibiotics is effective:

- a) SALPRAZ 40 mg twice daily
  - plus amoxicillin 1000 mg (2x 500 mg) twice daily
  - plus clarithromycin 500 mg twice daily
- b) SALPRAZ 40 mg twice daily
  - plus metronidazole 400 mg in the morning and 600 mg at night
  - plus clarithromycin 500 mg twice daily
- c) SALPRAZ 40 mg twice daily
  - plus amoxicillin 1000 mg (2x 500 mg) twice daily
  - plus metronidazole 400 mg in the morning and 600 mg at night
- d) SALPRAZ 40 mg twice daily
  - plus bismuth subcitrate 108 mg four times a day
  - plus metronidazole 200 mg three times a day and 400 mg at night
  - plus tetracycline 500 mg (2x 250 mg) four times a day

In combination therapy for eradication of *H. pylori* infection, the second dose of SALPRAZ 40 mg should be taken before the evening meal. The duration for combination therapy is 7 days. If further treatment with SALPRAZ is indicated to ensure ulcer healing, dosage recommendations as listed below for duodenal and gastric ulcers should be followed.

In *H. pylori* negative patients, the following dosage guidelines apply for monotherapy with pantoprazole.

**Duodenal Ulcer**

SALPRAZ 40 mg (one tablet) should be given once a day. In most patients freedom from symptoms is achieved rapidly and healing generally occurs within two weeks. If a two week period of treatment is not sufficient, healing will be achieved in almost all cases within a further two weeks.

**Gastric Ulcer**
SALPRAZ 40 mg (one tablet) should be given once a day. In most patients freedom from symptoms is achieved rapidly and healing usually takes four weeks. If a four week period of treatment is not sufficient, healing will usually be achieved in a further four weeks.

Lesions Refractory to H₂-receptor Antagonists

SALPRAZ 40 mg (one tablet) should be given once a day. In most patients freedom from symptoms is achieved rapidly and healing usually takes four weeks. If a four week period of treatment is not sufficient, healing will usually be achieved in the majority of patients in a further four weeks. In a small group of patients, there may be benefit in extending pantoprazole therapy to a total of 12 weeks.

Zollinger-Ellison Syndrome

The number of SALPRAZ 40 mg tablets should be individually adjusted so that the acid output remains below 10 mmol/L. No fixed period of time is proposed for treatment of Zollinger-Ellison syndrome.

Gastroesophageal Reflux Disease (GORD)

Symptomatic GORD (treatment of symptomatic reflux): the recommended dosage is one SALPRAZ 20 mg tablet per day for adults and children aged over 5 years. If symptom control has not been achieved after four weeks treatment with SALPRAZ 20 mg tablets daily, further investigation is recommended, for example, endoscopy.

Treatment of Reflux Oesophagitis

The recommended oral dosage is one SALPRAZ 20 or 40 mg tablet per day. In children over 5 years of age, the dosage should be adjusted according to weight – SALPRAZ 20 mg (for children 19–35 kg) or SALPRAZ 40 mg (for children > 35 kg) per day. A four week period is usually required for healing, however if this is not sufficient, healing will usually be achieved within a further four weeks. This dosage may be increased up to pantoprazole 80 mg per day in adults.

Treatment duration in children with symptomatic GORD or reflux oesophagitis should not exceed 8 weeks.

Maintenance of Healed Reflux Oesophagitis in Patients Previously Treated for Moderate to Severe Reflux Oesophagitis

For long-term management, a maintenance dose of one SALPRAZ 20 or 40 mg tablet/day is recommended, dependent upon patient response.

Prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous nonselective NSAID treatment

The recommended oral dosage is one SALPRAZ 20 mg tablet per day.

Use in Children

There is insufficient experience in children under 5 to justify a general recommendation.

Use in the Elderly

The usual daily dosage of 20 or 40 mg can be given.

During combination therapy for the eradication of H. pylori, elderly patients should receive the recommended pantoprazole dose of 40 mg twice daily for a 1-week treatment period.

Impaired Renal Function

The usual daily dose of 20 or 40 mg can be given.

Combination therapy for the eradication of H. pylori should not be used in patients with moderate to severe renal dysfunction as no data are available on efficacy and safety in this population.
**Impaired Hepatic Function**
Combination therapy for eradication of H. pylori should not be used in patients with moderate to severe hepatic dysfunction as no data are available on efficacy and safety in this population.

Pantoprazole is contraindicated in patients with cirrhosis or severe liver disease (see section 4.3 Contraindications).

With milder forms of liver disease, the minimum effective dose has not been determined and the initial dose should be reduced.

**4.3 CONTRAINDICATIONS**
Known hypersensitivity to pantoprazole, substituted benzimidazoles or any other components of the formulation; or in cases of cirrhosis or severe liver disease.

Combination therapy for eradication of H. pylori is contraindicated in patients with known hypersensitivity to any of the antibiotics proposed for combination therapy for eradication of H. pylori or in patients with moderate to severe hepatic or renal dysfunction. The product information for the individual components of the combination H. pylori eradication therapy should be consulted for any further contraindications.

Pantoprazole, like other proton pump inhibitors, should not be co-administered with HIV protease inhibitors, such as atazanavir or nelfinavir (see section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

**4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**

**Check the Following Before Use**
In the case of combination therapy for the eradication of H. pylori, the product information for the antibiotics used in the combination should be observed.

In the presence of any alarm symptoms (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with pantoprazole may alleviate symptoms and delay diagnosis. Further investigation is to be considered if symptoms persist despite adequate treatment.

**Clostridium difficile**
PPI therapy may be associated with an increased risk of Clostridium difficile infection.

Pantoprazole, like all proton pump inhibitors, might be expected to increase the counts of bacteria normally present in the upper gastrointestinal tract. Treatment with pantoprazole may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella, Campylobacter and Clostridium difficile.

**Influence on Vitamin B₁₂ Absorption**
Pantoprazole, as all acid-blocking medicines, may reduce the absorption of cyanocobalamin (vitamin B₁₂) due to hypochlorhydria or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B₁₂ absorption (such as the elderly) on long-term therapy and in patients with Zollinger-Ellison Syndrome and other pathological hypersecretory conditions requiring long-term treatment, or, if respective clinical symptoms are observed. Rare cases of cyanocobalamin (vitamin B₁₂) deficiency following acid-blocking therapy have been reported.

**Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)**
Use of SALPRAZ 20 mg for prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective NSAIDs should be restricted to patients who require continued non-selective NSAID treatment and have an increased risk of developing gastrointestinal complications. The increased risk should be assessed
according to individual risk factors, e.g. high age (> 65 years), history of gastric or duodenal ulcer or upper gastrointestinal bleeding.

**Subacute Cutaneous Lupus Erythematosus (SCLE)**
Proton pump inhibitors are associated in rare cases with the occurrence of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the healthcare professional should consider stopping the product.

**Bone Fracture**
PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-doses; defined as multiple daily doses, and long-term PPI therapy (a year or longer).

**Acute Interstitial Nephritis**
Acute interstitial nephritis has been observed in patients taking PPIs including pantoprazole. Acute interstitial nephritis may occur at any point during PPI therapy and is generally associated to an idiopathic hypersensitivity reaction. Discontinue pantoprazole if acute interstitial nephritis develops.

**Hypomagnesaemia**
Hypomagnesaemia has been rarely reported in patients treated with PPIs for at least three months (in most cases after a year of therapy). Serious consequences of hypomagnesaemia include tetany, arrhythmia, and seizure.

**Monitoring**
In long-term treatment, especially when exceeding a treatment period of one year, patients should be kept under regular surveillance.

Patients being treated for symptomatic GORD with SALPRAZ 20 mg who do not respond after four weeks should be investigated.

**General Toxicity**
**Gastrointestinal System**
Treatment with pantoprazole causes dose-dependent hypergastrinaemia as a result of inhibition of gastric acid secretion. Gastrin has a trophic effect on the gastric mucosa, and increases in gastric weight have been observed in rats and dogs to be dependent upon both dose and duration of treatment. Accompanying histopathological changes in the gastric mucosa were increased height, dilatation of fundic glands, chief cell hyperplasia and/or atrophy and parietal cell hyperplasia or vacuolation/degeneration. Increased density of enterochromaffin-like (ECL) cells was observed after 12 months treatment at dose levels from 5mg/kg/day in rats and 2.5mg/kg/day in dogs; with estimated exposures at these doses at, or below, the clinical exposure, all changes were reversible after various recovery periods. Since these gastric effects are a consequence of the pharmacological effect of acid secretion inhibition, no-effect doses were not established in all instances.

Although rats might be more susceptible to this effect than other species because of their high ECL cell density and sensitivity to gastrin, ECL cell hyperplasia occurs in other species, including mice and dogs, and has been observed in one of two clinical trials in which ECL cell density was measured (a 2-fold increase was observed in study RR126/97 after up to 5 years of treatment with regular and high doses, but no increase was observed in study RR125/97). No dysplastic or neoplastic changes were observed in gastric endocrine cells in either study.

**Ocular Toxicity and Dermal Phototoxicity/Sensitivity**
Studies have shown that pantoprazole is retained in low levels in the eyes and skin of pigmented rats. It is likely that the retention reflects a reversible association with melanin. Animal studies investigating the potential for
phototoxicity/photosensitivity have not been conducted. A 2-week dog study, conducted specifically to investigate the effects on the eye and ear, did not reveal any changes relating to pantoprazole treatment, but the doses chosen were relatively low (with exposures (AUC) of 0.2- to 10-fold (oral) and 1- to 2-fold (IV) the clinical exposure). No ophthalmological changes or changes in electoretinographs were observed in cynomolgus monkeys at IV doses of up to 15mg/kg/day (up to 7- to 9-fold the clinical exposure of the 40 mg IV dose) for 4 weeks.

**Use in Hepatic Impairment**
See section 4.2 Dose and Method of Administration.

**Use in Renal Impairment**
See section 4.2 Dose and Method of Administration.

**Use in the Elderly**
No dose adjustment is necessary in elderly patients (see sections 4.2 Dose and Method of Administration – Use in the Elderly; 4.4 Special Warnings and Precautions for Use – Influence on Vitamin B\textsubscript{12} Absorption and 5.2 Pharmacokinetic Properties – Special Populations).

**Paediatric Use**
To date there is insufficient experience with treatment in children under 5 to justify a general recommendation.

**Effects on Laboratory Tests**
Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, proton pump inhibitor treatment should be stopped 14 days before CgA measurements.

**4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**

Pantoprazole is metabolised in the liver via the cytochrome P450 enzyme system. A study using human liver microsomes suggested that the P450 enzymes CYP2C19 and CYP3A4 are involved in its metabolism. In addition, CYP2D6 and CYP2C9-10 were implicated in another study. An interaction of pantoprazole with other drugs or compounds which are metabolised using the same enzyme system cannot be excluded. However, no clinically significant interactions were observed in specific tests with a number of such drugs or compounds, namely carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and the low dose oral contraceptive Triphasil\textsuperscript{®} (levonorgestrel and ethinylestradiol). There was also no interaction with a concomitantly administered antacid (aluminium hydroxide hydrate and magnesium hydroxide).

Treatment of dogs with IV famotidine shortened the duration of the pH elevation effect of pantoprazole.

Four cross-over pharmacokinetic studies designed to examine any interactions between pantoprazole and the drugs clarithromycin, amoxicillin and metronidazole, conducted in 66 healthy volunteers, showed no interactions.

**Drugs with pH-Dependent Absorption Pharmacokinetics**

As with all acid suppressant medications, the absorption of drugs whose bioavailability is pH dependent (e.g. ketoconazole, itraconazole, posaconazole, erlotinib) might be altered due to the decrease in gastric acidity.

**HIV Protease Inhibitors**

It has been shown that co-administration of atazanavir 300 mg/ ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg single dose) to healthy volunteers resulted in a substantial reduction in the bioavailability of atazanavir. The absorption of atazanavir is pH dependent. Therefore, proton pump inhibitors, including pantoprazole, should not be co-administered with HIV protease inhibitors for which
absorption is dependent on acidic intragastric pH, such as atazanavir or nelfinavir (see section 4.3 Contraindications).

**Mycophenolate Mofetil**
Co-administration of PPIs in healthy subjects and in transplant patients receiving mycophenolate mofetil has been reported to reduce the exposure to the active metabolite, mycophenolic acid. This is possibly due to a decrease in mycophenolate mofetil solubility at an increased gastric pH. The clinical relevance of reduced mycophenolic acid exposure on organ rejection has not been established in transplant patients receiving PPIs and mycophenolate mofetil. Use pantoprazole with caution in transplant patients receiving mycophenolate mofetil.

**Methotrexate**
Concomitant use with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities.

**Drugs that Inhibit or Induce CYP 2C19 (tacrolimus, fluvoxamine)**
Concomitant administration of pantoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolisers of CYP2C19. Inhibitors of CYP2C19, such as fluvoxamine, would likely increase the systemic exposure of pantoprazole.

**Coumarin Anticoagulants (phenprocoumon or warfarin)**
Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenprocoumon or international normalised ratio (INR). However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin or phenprocoumon concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even death. Therefore, in patients being treated with coumarin anticoagulants (e.g. warfarin or phenprocoumon), monitoring of prothrombin time / INR is recommended after initiation, termination or during irregular use of pantoprazole.

### 4.6 FERTILITY, PREGNANCY AND LACTATION

**Effects on Fertility**
Pantoprazole at oral doses up to 500 mg/kg/day in male rats and 450 mg/kg/day in female rats (estimated exposure at least 60-fold the clinical exposure from the 40 mg tablet) was found to have no effect on fertility and reproductive performance.

**Use in Pregnancy**
Pregnancy Category: B3

Teratological studies in rats and rabbits gave no evidence of a teratogenic potential for pantoprazole. In oral studies in rats, dose dependent toxic effects were observed on fetuses and pups: increased prenatal and postnatal deaths (450 mg/kg/day) (AUC exposure approximately 60-times the clinical exposure of the 40 mg oral dose), reduced fetal weight (greater than or equal to 150 mg/kg/day) (AUC exposure approximately 18-fold the clinical exposure) and delayed skeletal ossification and reduced pup growth (greater than or equal to 15 mg/kg/day) (approximately clinical exposure). For the latter, a no effect dose of 5 mg/kg was established. Doses of 450 mg/kg/day were maternotoxic and may have been associated with dystocia and incomplete parturition. Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentrations of pantoprazole in the fetus are increased shortly before birth regardless of the route of administration.

The significance of these findings in humans is unknown. As there is no information on the safety of the drug during pregnancy in women, pantoprazole should not be used during pregnancy unless the benefit clearly outweighs the potential risk to the fetus.
Use in Lactation

Oral administration of pantoprazole to rats from late gestation to weaning at doses of 10 mg/kg/day (AUC exposure approximately the clinical exposure of the 40 mg oral dose) or greater decreased pup growth. A transient effect on one of a series of development tests (startle response) was only evident in the 30mg/kg/day (AUC exposure approximately 3-fold the clinical exposure) group at an age when male and female offspring showed lower body weights, paralleled with lower brain weight, than the controls. The significance of these findings for humans is unknown, and there is currently no information on the safety of pantoprazole during breast feeding in humans. Excretion into human milk has been reported. Therefore, pantoprazole should only be used during lactation if the benefits clearly outweigh the risks.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Pantoprazole does not exert its pharmacological action centrally, therefore it is not expected to adversely affect the ability to drive or use machines, however, adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8 Adverse Effects (Undesirable Effects)). If affected, patients should not drive or operate machines.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Pantoprazole tablets are well tolerated. Most of the adverse reactions seen with treatment are of mild or moderate intensity. The following adverse reactions have been reported in patients receiving pantoprazole alone or in combination with antibiotics for H. pylori eradication in clinical trials and post-marketing surveillance.

Adverse reactions within each body system are listed in descending order of frequency (very common: ≥10%; common: ≥1% and <10%; uncommon: ≥0.1% and <1%; rare ≥0.01% and <0.1%; very rare: <0.01%; not known: cannot be estimated from the available data).

These include the following:

General disorders and administration site conditions:

Uncommon: fatigue and malaise, asthenia and increased sweating.
Rare: fever, peripheral oedema and increased body temperature.
Very rare: flushing, substernal chest pain and hot flushes.

Cardiovascular disorders, general:

Rare: hypertension.
Very rare: circulatory collapse.

Nervous system disorders:

Uncommon: headache, dizziness.
Rare: taste disorders, metallic taste.
Very rare: reduced movement and speech disorder, changes to the sense of smell and taste.

Gastrointestinal system disorders:

Uncommon: diarrhoea, nausea/vomiting, abdominal distension and bloating, constipation, dry mouth, abdominal pain and discomfort.
Rare: rectal disorder and colonic polyp.
Very rare: faecal discoloration and increased saliva.
Not known: severe eructation, withdrawal of long-term PPI therapy can lead to aggravation of acid related symptoms and may result in rebound acid hypersecretion.

**Hearing and vestibular disorders:**
Very rare: tinnitus.

**Immune system disorders:**
Rare: hypersensitivity (including anaphylactic reactions and anaphylactic shock).

**Hepatobiliary disorders:**
Uncommon: increased liver enzymes (transaminases, gamma-GT).
Rare: bilirubin increased.
Very rare: hepatocellular failure, cholestatic hepatitis, jaundice.
Not known: hepatocellular injury.
The occurrence of severe hepatocellular damage leading to jaundice or hepatic failure having a temporal relationship to the intake of pantoprazole has been reported with a frequency of approximately one in a million patients.

**Metabolism and nutrition disorders:**
Rare: hyperlipidaemias and lipid increases (triglycerides, cholesterol), weight changes.
Not known: hyponatraemia, hypomagnesaemia.

**Musculoskeletal and connective tissue disorders:**
Rare: myalgia and arthralgia.
Very rare: pain including skeletal pain.
Not known: fracture of wrist, hip and spine.

**Renal and urinary disorders:**
Very rare: interstitial nephritis.

**Platelet, bleeding, clotting disorders:**
Very rare: increased coagulation time.

**Psychiatric disorders:**
Uncommon: sleep disorders.
Rare: depression, hallucination, disorientation and confusion, especially in predisposed patients, as well as the aggravation of these symptoms in the case of pre-existence.
Very rare: anxiety.

**Blood and lymphatic disorders:**
Rare: anaemia, agranulocytosis.
Very rare: leucopenia, thrombocytopenia, pancytopenia.

**Resistance mechanism disorders:**
Rare: sepsis.

**Respiratory system disorders:**
Very rare: dyspnoea.

**Reproductive system and breast disorders:**
Rare: gynaecomastia

**Skin and subcutaneous tissue disorders:**
Uncommon: pruritus, skin rash/exanthema/eruption.
Rare: angioedema, urticaria.
Very rare: flushing, severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, Lyell syndrome and photosensitivity.
Not known: subacute cutaneous lupus erythematosus

**Eye disorders:**
Uncommon: reports of disturbances in vision (blurred vision).
Very rare: conjunctivitis.

Table 1: Incidence (%) of Common (> 1%) and Uncommon (< 1%) Adverse Events in Clinical Trials of Triple Therapy Containing Pantoprazole in Combination with Two Antibiotics for *H. pylori* Eradication

<table>
<thead>
<tr>
<th>Event</th>
<th>PCM/T</th>
<th>PAC</th>
<th>PAM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 725</td>
<td>N = 492</td>
<td>N = 146</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>4.8</td>
<td>10.0</td>
<td>7.5</td>
</tr>
<tr>
<td>Taste bitter</td>
<td>4.0</td>
<td>3.0</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>3.7</td>
<td>1.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Taste metallic</td>
<td>2.1</td>
<td>0.2</td>
<td>0</td>
</tr>
<tr>
<td>Upper abdominal pain</td>
<td>1.9</td>
<td>1.4</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>1.8</td>
<td>1.8</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1.4</td>
<td>0.6</td>
<td>0</td>
</tr>
<tr>
<td>Tongue pain</td>
<td>1.2</td>
<td>0.8</td>
<td>0</td>
</tr>
<tr>
<td>Liver enzymes increased</td>
<td>1.2</td>
<td>0.2</td>
<td>0</td>
</tr>
<tr>
<td>Tiredness</td>
<td>1.1</td>
<td>0</td>
<td>0.7</td>
</tr>
<tr>
<td>Loose stools</td>
<td>1.0</td>
<td>0.8</td>
<td>0</td>
</tr>
<tr>
<td>Oral moniliasis</td>
<td>1.0</td>
<td>0.4</td>
<td>0</td>
</tr>
<tr>
<td>Buccal inflammation</td>
<td>1.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Exanthemata</td>
<td>0.4</td>
<td>1.2</td>
<td>0.7</td>
</tr>
<tr>
<td>Heartburn</td>
<td>0.4</td>
<td>0.4</td>
<td>2.7</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>0.1</td>
<td>0.6</td>
<td>1.4</td>
</tr>
<tr>
<td>Rash</td>
<td>0.1</td>
<td>0.6</td>
<td>1.4</td>
</tr>
<tr>
<td>At least one of the above</td>
<td>34</td>
<td>29</td>
<td>20</td>
</tr>
</tbody>
</table>

*T = tinidazole, used in place of metronidazole in one clinical study

Table 2: Adverse Events (≥ 1%) Reported in a Clinical Trial Comparing Quadruple and Triple Therapies for *H. pylori* Eradication Regardless of Causality

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>PBMT N = 422</th>
<th>BMT N = 600</th>
<th>PAC N = 368</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin and Appendages Disorder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>7 (1.7%)</td>
<td>16 (2.7%)</td>
<td>4 (1.1%)</td>
</tr>
<tr>
<td>Pruritus ani</td>
<td>-</td>
<td>7 (1.2%)</td>
<td>-</td>
</tr>
<tr>
<td>Central &amp; Peripheral Nervous System Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>49 (11.6%)</td>
<td>65 (10.8%)</td>
<td>38 (10.3%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>30 (7.1%)</td>
<td>38 (6.3%)</td>
<td>25 (6.8%)</td>
</tr>
<tr>
<td>Special Senses Other, Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taste perversion</td>
<td>45 (10.7%)</td>
<td>65 (10.8%)</td>
<td>67 (18.2%)</td>
</tr>
</tbody>
</table>
Psychiatric Disorders
Anorexia 11 (2.6%) 19 (3.2%) 17 (4.6%)
Somnolence - 8 (1.3%) -
Depression - - 4 (1.1%)
Gastrointestinal Disorders
Diarrhoea 49 (11.6%) 56 (9.3%) 37 (10.1%)
Nausea 38 (9.0%) 58 (9.7%) 34 (9.2%)
Abdominal pain 27 (6.4%) 37 (6.2%) 24 (6.5%)
Vomiting 7 (1.7%) 12 (2.0%) 8 (2.2%)
Faeces discoloured 7 (1.7%) 18 (3.0%) -
Tongue discolouration 10 (2.4%) 11 (1.8%) -
Mouth dry - 13 (2.2%) 4 (1.1%)
Constipation - - 8 (2.2%)
Dyspepsia - 6 (1.0%) -
Respiratory System Disorders
Pharyngitis 8 (1.9%) 9 (1.5%) 7 (1.9%)
Body as a Whole – General Disorders
Influenza-like symptoms 15 (3.6%) 12 (2.0%) 14 (3.8%)
Chest pain 5 (1.2%) - 4 (1.1%)
Resistance Mechanism Disorders
Monilasis 6 (1.4%) - 5 (1.4%)
- events reported by < 1%


<table>
<thead>
<tr>
<th>Overall Children</th>
<th>Number of AE</th>
<th>Number of Patients with AE</th>
<th>% Patients with AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>201</td>
<td>66</td>
<td>26.4</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>67</td>
<td>34</td>
<td>13.6</td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
<td>58</td>
<td>33</td>
<td>13.2</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>32</td>
<td>14</td>
<td>5.6</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>20</td>
<td>13</td>
<td>5.2</td>
</tr>
<tr>
<td>Cough</td>
<td>20</td>
<td>13</td>
<td>5.2</td>
</tr>
</tbody>
</table>

Reporting Suspected Adverse Effects
Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

There are no known symptoms of overdosage in humans. In individual cases, 240mg was administered i.v or p.o. and was well tolerated. As pantoprazole is extensively protein bound, it is not readily dialysable. As in any case of overdosage, treatment should be symptomatic and supportive measures should be utilised.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of Action
Pantoprazole is a proton pump inhibitor (PPI). It inhibits specifically and dose-proportionately H+/K+-ATPase, the enzyme which is responsible for gastric acid secretion in the parietal cells of the stomach.
The substance is a substituted benzimidazole which accumulates in the acidic environment of the parietal cells after absorption. There, it is converted into the active form, a cyclic sulfenamide which binds to the H+/K+-ATPase, thus inhibiting the proton pump and causing potent and long-lasting suppression of basal and stimulated gastric acid secretion. As pantoprazole acts distal to the receptor level, it can influence gastric acid secretion irrespective of the nature of the stimulus (acetylcholine, histamine, gastrin).

Pantoprazole's selectivity is due to the fact that it only exerts its full effect in a strongly acidic environment (pH < 3), remaining mostly inactive at higher pH values. As a result, its complete pharmacological, and thus therapeutic effect, can only be achieved in the acid secretory parietal cells. By means of a feedback mechanism this effect is diminished at the same rate as acid secretion is inhibited.

As with other proton pump inhibitors and H2-receptor inhibitors, treatment with pantoprazole causes a reduced acidity in the stomach and thereby an increase in gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible.

Clinical Trials in Adults

*Helicobacter pylori* (H. pylori) is associated with duodenal and gastric ulcer disease in about 95 and 70% of patients, respectively. *H. pylori* is the major factor in the development of gastritis and ulcers in such patients. Recent evidence also suggests a causative link between *H. pylori* and gastric carcinoma. An attempt to eradicate *H. pylori* is recommended in most patients with duodenal and gastric ulcer where the latter is not caused by NSAID ingestion (see section 4.2 Dose and Method of Administration). In an experimental study in mice, pantoprazole at a dose of 100 mg/kg t.i.d. increased the inhibitory potency of amoxicillin, clarithromycin and tetracycline against *Helicobacter felis*.

Eradication of *H. pylori*

The clinical trial program of pantoprazole for eradication of *H. pylori* has investigated four therapy combinations. A summary of the clinical trials is provided in the following tables:

Table 3: Clinical Trials Comparing Triple Therapies Containing Pantoprazole in Combination with Two Antibiotics

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Therapy Scheme (mg per day)</th>
<th>Days of Medication</th>
<th>N (MITT)</th>
<th>Indication (N)</th>
<th>Eradication Rate (MITT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BY1023</td>
<td>Open hades</td>
<td>PAC-P 80/2000/1000-40</td>
<td>7/7/7-7</td>
<td>60</td>
<td>DU (60)</td>
<td>81.7%</td>
</tr>
<tr>
<td>VMG405</td>
<td>Open</td>
<td>PAC-P 80/2000/1000-40</td>
<td>7/7/7-7</td>
<td>150</td>
<td>DU (297)</td>
<td>90.0%</td>
</tr>
<tr>
<td>VMG411</td>
<td>Open randomised</td>
<td>PAC-P 80/2000/1000-40</td>
<td>7/7/7-7</td>
<td>147</td>
<td></td>
<td>89.8%</td>
</tr>
<tr>
<td>PCM-P 80/1000/1000-40</td>
<td>7/7/7-7</td>
<td>147</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BGS010</td>
<td>Single blind randomised</td>
<td>PAC 80/2000/1000</td>
<td>14/7/7</td>
<td>33</td>
<td>DU (67)</td>
<td>78.8%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAC 80/2000/1000</td>
<td>14/14/14</td>
<td>34</td>
<td></td>
<td>91.2%</td>
</tr>
<tr>
<td>BF005</td>
<td>Double blind randomised</td>
<td>PAC 80/2000/1000</td>
<td>7/7/7</td>
<td>96</td>
<td>NUD (192)</td>
<td>75.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAC 40/2000/1000</td>
<td>7/7/7</td>
<td>96</td>
<td></td>
<td>56.3%</td>
</tr>
</tbody>
</table>

Regimen: Pantoprazole/Clarithromycin/Metronidazole (PCM)

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Therapy Scheme (mg per day)</th>
<th>Days of Medication</th>
<th>N (MITT)</th>
<th>Indication (N)</th>
<th>Eradication Rate (MITT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VMG401</td>
<td>Open</td>
<td>PCM 80/500/800</td>
<td>7/7/7</td>
<td>30</td>
<td>DU (8) GU (3) HU (6) FD (13)</td>
<td>80.0%</td>
</tr>
</tbody>
</table>
Table 4: A Clinical Trial Comparing Quadruple and Triple Therapies with or without Pantoprazole

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Therapy Scheme (mg per day)</th>
<th>Days of Medication</th>
<th>N (ITT)</th>
<th>Indication</th>
<th>Eradication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>96-AGPP-001</td>
<td>Open randomised</td>
<td>PBMT 80/432/1000/2000</td>
<td>7/7/7</td>
<td>134</td>
<td>NUD</td>
<td>82%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAC 80/2000/1000</td>
<td>7/7/7</td>
<td>134</td>
<td>NUD</td>
<td>78%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BMT 432/1000/2000</td>
<td>14/14/14</td>
<td>137</td>
<td>NUD</td>
<td>69%</td>
</tr>
</tbody>
</table>

Regimen: Pantoprazole/Bismuth/Metronidazole/Tetracycline (PBMT)

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Therapy Scheme (mg per day)</th>
<th>Days of Medication</th>
<th>N (ITT)</th>
<th>Indication</th>
<th>Eradication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>VMG402</td>
<td>Double blind randomised</td>
<td>PCM 80/1000/1000</td>
<td>7/7/7</td>
<td>121</td>
<td>DU (244)</td>
<td>73.6%</td>
</tr>
<tr>
<td>VMG404</td>
<td>Open</td>
<td>PCM-P 80/1000/1000-40</td>
<td>14/14/10-14</td>
<td>62</td>
<td>DU (62)</td>
<td>74.2%</td>
</tr>
<tr>
<td>VMG411</td>
<td>Open randomised</td>
<td>PAC-P 80/2000/1000-40</td>
<td>See results for PAC regime above</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FK3049</td>
<td>Open randomised</td>
<td>PCM-P 80/1500/1500-40</td>
<td>7/7/7-21</td>
<td>136</td>
<td>DU (277)</td>
<td>89.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PC-P 80/1500-40</td>
<td>14/14/-14</td>
<td>141</td>
<td></td>
<td>58.9%</td>
</tr>
</tbody>
</table>

Regimen: Pantoprazole/Amoxicillin/Metronidazole (PAM)

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Therapy Scheme (mg per day)</th>
<th>Days of Medication</th>
<th>N (ITT)</th>
<th>Indication</th>
<th>Eradication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>VMG406</td>
<td>Open</td>
<td>PAM-P 80/2000/1000-40</td>
<td>7/7/7-21</td>
<td>48</td>
<td>DU (24)</td>
<td>81.3%</td>
</tr>
<tr>
<td>VMG407</td>
<td>Open</td>
<td>PAM-P 80/2250/1200-40</td>
<td>10/10-18</td>
<td>65</td>
<td>DU (65)</td>
<td>78.5%</td>
</tr>
<tr>
<td>VMG409</td>
<td>Open</td>
<td>PAM 80/2000/1000</td>
<td>7/7/7</td>
<td>30</td>
<td>GU (6)</td>
<td>70.0%</td>
</tr>
</tbody>
</table>

Regimen: Pantoprazole/Amoxicillin/Clarithromycin (PAC)

| P       | pantoprazole     | MITT | modified intent to treat |
| PAC     | pantoprazole/amoxicillin/clarithromycin | DU | duodenal ulcer |
| PCM     | pantoprazole/clarithromycin/metronidazole | GU | gastric ulcer |
| PAM     | pantoprazole/amoxicillin/metronidazole | HU | history of ulcer |
| PBMT    | pantoprazole/bismuth/metronidazole/tetracycline | NUD | non-ulcer dyspepsia |
| e       | bismuth/metronidazole/tetracycline | FD | functional dyspepsia |
| BMT     | bismuth/metronidazole/tetracycline | GAS | gastritis |
| PC      | pantoprazole/clarithromycin | ERO | erosions |

Treatment of Symptomatic Reflux (GORD)

The relief of symptoms of reflux in patients who showed no oesophageal lesions on endoscopy has been shown in the following double blind, multi-centre, placebo-controlled study (245/98) using pantoprazole 20 mg once daily. Overall, 219 patients were enrolled in the study. Each patient was to have a normal oesophagus as assessed by endoscopy and to have suffered from at least one episode of heartburn of at least moderate intensity on all three days prior to inclusion into the study. Additionally, patients were to have a history of reflux symptoms...
(heartburn, acid eructation, pain on swallowing) for at least three months prior to entry into the study. Efficacy of pantoprazole 20 mg is shown in the table below.

Table 5: Efficacy of Pantoprazole 20 mg in Treatment of Symptomatic GORD

<table>
<thead>
<tr>
<th></th>
<th>1 WEEK</th>
<th>2 WEEKS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pastoprazole 20 mg</td>
<td>Placebo</td>
</tr>
<tr>
<td>Per protocol n = 211 (week 1) n = 204 (week 2)</td>
<td>69%</td>
<td>30%</td>
</tr>
<tr>
<td>Intention to treat n = 219</td>
<td>67%</td>
<td>32%</td>
</tr>
</tbody>
</table>

Acute Treatment of Mild Reflux Oesophagitis

In two randomised, double-blind, multicentre studies (BGSA006 and FK3034) 410 patients with mild gastrooesophageal reflux disease (GORO) (Savary-Miller stage 1) were treated with either pantoprazole 20 mg once daily before breakfast or ranitidine 300 mg once daily at bedtime. Superiority of pantoprazole 20 mg in terms of healing rates compared to ranitidine after four and eight weeks is shown in the Table below. The difference in healing rates was statistically significant at all time points in the intention-to-treat and per protocol patient groups.

Table 6: Endoscopic Healing of Stage 1 Oesophagitis (Intention-to-Treat)

<table>
<thead>
<tr>
<th>Trial/group</th>
<th>n</th>
<th>% patients healed</th>
<th>4 weeks</th>
<th>8 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>BGSA006</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>101</td>
<td>73.3</td>
<td>83.2</td>
<td></td>
</tr>
<tr>
<td>Ranitidine</td>
<td>100</td>
<td>49.0</td>
<td>69.0</td>
<td></td>
</tr>
<tr>
<td>Difference</td>
<td></td>
<td>p&lt; 0.05</td>
<td>p&lt; 0.05</td>
<td></td>
</tr>
<tr>
<td>FK3034</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>105</td>
<td>66.7</td>
<td>74.3</td>
<td></td>
</tr>
<tr>
<td>Ranitidine</td>
<td>104</td>
<td>52.9</td>
<td>60.6</td>
<td></td>
</tr>
<tr>
<td>Difference</td>
<td></td>
<td>p&lt; 0.05</td>
<td>p&lt; 0.05</td>
<td></td>
</tr>
</tbody>
</table>

Maintenance of Healed Reflux Oesophagitis in Patients Previously Treated for Moderate to Severe Reflux Oesophagitis

Three randomised, double-blind, parallel group trials examined the efficacy of pantoprazole in the maintenance of healed reflux oesophagitis in patients aged 18 to 88 years treated for moderate to severe reflux oesophagitis over 12 months. The primary endpoint was time to endoscopically confirmed relapse; however, the median was not reached in the pantoprazole groups at the end of 12 months. The results for the incidence of relapse in patients with data from at least one follow-up visit are outlined in the table below.

Table 7: Incidence of Relapse 1 (%) of Reflux Oesophagitis 2 in Controlled Trials of 12 Months Duration (evaluable patients)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Pantoprazole 20 mg/day</th>
<th>Pantoprazole 40 mg/day</th>
<th>Ranitidine 150 mg/day</th>
<th>Difference (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FK 3028</td>
<td>25%</td>
<td>22%</td>
<td>-</td>
<td>2.7%</td>
</tr>
<tr>
<td>(n=221)</td>
<td></td>
<td>(n=212)</td>
<td></td>
<td>(-5, 10)</td>
</tr>
</tbody>
</table>
1 endoscopically confirmed

2 patients were enrolled in the study with Savary-Miller stage 2 to 3 reflux oesophagitis. Patients were initially healed of their reflux oesophagitis with a short-term treatment of up to 8 weeks with either pantoprazole or omeprazole. Following healing of reflux oesophagitis, patients were then enrolled in the long-term prevention study for up to 12 months. Relapse was defined as endoscopically confirmed presence of reflux oesophagitis.

Pantoprazole 20 mg and 40 mg/day doses were therapeutically equivalent based on the pre-defined equivalence criterion of the 90% confidence interval of the difference between doses being within ± 20%.

Four uncontrolled trials with varying periods of follow-up support the long-term efficacy of pantoprazole 40 to 80 mg/day in the maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. Two of the trials included patients with gastric and duodenal ulcer. The incidence of relapse at 1 year was 12 to 15%, 2 years 22 to 25% and 6 years 40%.

Safety data is available from the 1584 patients involved in the 7 long-term clinical studies. 904 patients have been treated with pantoprazole for at least 1 year, and 273, 112, 68, 47 and 17 have been treated for at least 2, 3, 4, 5 and 6 years, respectively. In total, 108 (6.8%) patients experienced serious adverse events (EC definition), of which all but 6 were classified as being causally unrelated to pantoprazole (4 cases with 40 mg pantoprazole: colonic polyp; abdominal pain and rectal disorder; diarrhoea and abdominal pain, sepsis versus 2 cases with high-dose pantoprazole: anaemia and hypertension (see section 4.8 Adverse Effects (Undesirable Effects)). Additionally, in the open on-going studies, patients were assessed by biopsy and no evidence of dysplastic or neoplastic endocrine growth was found.

Prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective NSAIDs in increased risk patients with a need for continuous non-selective NSAID treatment:

Two randomised, double-blind, multi-centre studies (205/2000 and 129/2000) examined the efficacy and safety of pantoprazole in the prevention of NSAID-associated gastroduodenal ulcers, petechiae, erosions and dyspeptic symptoms in patients with arthritis on continuous treatment with NSAIDs and an increased risk of developing gastrointestinal lesions.

The primary endpoint for both studies was the 'therapeutic failure' rate after six months, defined as 'endoscopic failure' (i.e. more than ten erosions or petechiae, peptic ulcer, reflux oesophagitis) or premature study termination due to at least 'likely' related adverse event or due to severe gastrointestinal symptoms.

**Study 205/2000**

A total of 515 patients were included in the study. Patients were randomised to receive either pantoprazole 20 mg daily (n = 257) or misoprostol 200 microgram twice daily (n = 258). Efficacy of pantoprazole 20 mg is shown in the table below.

### Table 8: Results, Efficacy

<table>
<thead>
<tr>
<th>Time Interval</th>
<th>Pantoprazole</th>
<th>Misoprostol</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients</td>
<td>257</td>
<td>258</td>
<td></td>
</tr>
<tr>
<td><strong>In remission with regard to</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic failure</td>
<td>89.3</td>
<td>70.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Endoscopic failure</td>
<td>94.7</td>
<td>85.7</td>
<td>0.005</td>
</tr>
<tr>
<td>Symptomatic failure</td>
<td>98.5</td>
<td>91.7</td>
<td>0.002</td>
</tr>
</tbody>
</table>
Pantoprazole 20 mg once daily was statistically significantly superior to misoprostol 200 microgram twice daily with regard to 'therapeutic failure' and to 'endoscopic failure'. Reflux oesophagitis was included as an efficacy endpoint in the study which may have biased the results in favour of pantoprazole. A causal association between NSAIDs and reflux oesophagitis has not been established. In addition, proton pump inhibitors such as pantoprazole have documented beneficial treatment effects on reflux oesophagitis while misoprostol (a prostaglandin E1 analogue) has negligible therapeutic effects.

**Study 129/2000**

A total of 595 patients were included into the study. Patients were randomised to receive either pantoprazole 20 mg daily (n = 196), pantoprazole 40 mg daily (n = 199) or omeprazole 20 mg daily (n = 200). Efficacy results are shown in the table below.

**Table 9: Results, Efficacy**

<table>
<thead>
<tr>
<th>Time Interval</th>
<th>Pantoprazole 20 mg</th>
<th>Pantoprazole 40 mg</th>
<th>Omeprazole 20 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients</td>
<td>196</td>
<td>199</td>
<td>200</td>
</tr>
<tr>
<td>In remission with regard to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic failure</td>
<td>0-6</td>
<td>89.8</td>
<td>93.1</td>
</tr>
<tr>
<td>Endoscopic failure</td>
<td>0-6</td>
<td>91.4</td>
<td>95.3</td>
</tr>
<tr>
<td>Symptomatic failure</td>
<td>0-6</td>
<td>98.1</td>
<td>100</td>
</tr>
</tbody>
</table>

All three treatments, pantoprazole 20 mg, pantoprazole 40 mg and omeprazole 20 mg, were proven to be of equivalent and high efficacy.

**Clinical Trials in Children**

In 2 studies, pantoprazole 20 mg or 40 mg daily was given to 189 children aged from 5 to 16 years with symptomatic GORD. A similar reduction in symptoms of GORD was reported with both doses in both studies.

### 5.2 PHARMACOKINETIC PROPERTIES

**Absorption**

**Adults**

After administration of enteric-coated tablets, pantoprazole is rapidly absorbed and the maximal plasma concentration appears after one single oral dose. After single and multiple oral doses, the median time to reach maximum serum concentrations was approximately 2.5 h, with a $C_{\text{max}}$ of approximately 1.2 $\mu$g/mL following a 20 mg dose. Terminal half-life is approximately 1 h. Pharmacokinetics do not vary after single or repeated administration. The plasma kinetics of pantoprazole are linear (in the dose range of 10 to 80 mg) after both oral and intravenous administration.

Pantoprazole is completely absorbed after oral administration. The absolute bioavailability of the tablet is approximately 77%. Concomitant intake of food had no influence on AUC and $C_{\text{max}}$ of the pantoprazole 40 mg tablet and thus its bioavailability.

**Distribution**

The serum protein binding of pantoprazole is approximately 98%. Volume of distribution is approximately 0.15 L/kg and clearance is approximately 0.1 L/h/kg.

**Metabolism**

Pantoprazole is extensively metabolised in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is
demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4.

There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. CYP2C19 displays a known genetic polymorphism due to its deficiency in some sub-populations (e.g. 3% of Caucasians and African-Americans and 17-23% of Asians). Although these sub-populations of slow pantoprazole metabolisers have elimination half-life values of 3.5 to 10.0 hours, they still have minimal accumulation (δ 23%) with once daily dosing.

**Excretion**

Pantoprazole is rapidly eliminated from serum and is almost exclusively metabolised in the liver. Renal elimination represents the most important route of excretion (approximately 80%) for the metabolites of pantoprazole, the rest are excreted with the faeces. The main metabolite in both the serum and urine is desmethyl-pantoprazole which is conjugated with the sulphate. The half-life of the main metabolites (approximately 1.5 h) is not much longer than that of pantoprazole.

**Special Populations**

**Hepatic Impairment**

In patients with liver cirrhosis given a single 40 mg tablet, the half-life increases to between 7 and 9 h and the AUC values are increased by a factor of 6 to 8 but the maximum serum concentration increases only slightly by a factor of 1.5 in comparison with healthy subjects. After a single 20 mg tablet, AUC increased 3-fold in patients with mild hepatic impairment and 5-fold in patients with severe hepatic impairment compared with healthy controls. Mean elimination half-life was 3.3 h in mild hepatic impairment and 6.0 h in severe hepatic impairment compared with 1.1 h in controls. The maximum serum concentration only increased slightly by a factor of 1.3 compared with healthy subjects.

**Renal Impairment**

In patients with renal impairment (including those undergoing dialysis) no dose reduction is required. Although the main metabolite is moderately increased, there is no accumulation. The half-life of pantoprazole is as short as in healthy subjects. Pantoprazole is poorly dialysable.

**Use in the Elderly**

The slight increase in AUC and C<sub>max</sub> in elderly volunteers compared with their younger counterparts is also not clinically relevant.

**Children**

Following administration of single oral doses of 20 mg or 40 mg pantoprazole to children aged 5 to 16 years, AUC and C<sub>max</sub> were in the same range as the corresponding values observed in adults.

Following administration of single IV doses of 0.8 or 1.6 mg/kg of pantoprazole to children aged 2 to 16 years, AUC and volume of distribution were in accordance with data from adults and there was no significant association between pantoprazole clearance and age or weight.

### 5.3 PRECLINICAL SAFETY DATA

**Genotoxicity**

A number of in vitro and in vivo genotoxicity assays covering mutagenicity, clastogenicity and DNA damage end points were conducted on pantoprazole and the results were generally negative. Exposures achieved in the in vivo tests in mice and rats were well in excess of exposures expected clinically. However, pantoprazole was clearly positive in carefully conducted cytogenetic assays in human lymphocytes in vitro, both in the presence and
absence of metabolic activation. Omeprazole was also positive in a comparable test conducted in the same laboratory, suggesting a possible class effect. A minute amount of radioactivity was bound to rat hepatic DNA after treatment with 200 mg/kg/day pantoprazole for 14 days. This is an estimated exposure 24-fold the clinical exposure from the 40 mg tablet. No distinct DNA-adduct has been detected.

Pantoprazole was found to be negative in the following studies: in vivo chromosome aberration assay in rat and bone marrow (126E/95), mouse lymphoma test (222E/95) and a gene mutation test in Chinese hamster ovary cells (in vitro) (188E/95). In addition, toxicokinetic studies were conducted in rats at the doses used in the bone marrow assay (50 to 1200 mg/kg) (56E/96) and in mice at the high dose from the earlier micronucleus test (710 mg/kg) (89E/96). Pantoprazole exposure was high with the respective rat and mouse plasma AUCs being 7- to 100- and 9- to 12-fold the clinical exposure from a 40 mg tablet.

**Carcinogenicity**

A two-year oral carcinogenicity study in Sprague Dawley rats at doses up to 200 mg/kg/day gastric carcinoids were found after pantoprazole treatment at doses greater than 0.5 mg/kg/day in females and greater than 5 mg/kg/day in males, with none observed in controls. The estimated exposure (based on AUC) from these doses are at, or below, clinical exposure from a 40 mg tablet. The development of gastric tumours is attributed to chronic elevation of serum gastrin levels with associated histopathological changes in the gastrointestinal system.

In both male and female rats, the development of hepatocellular adenomas was increased at doses greater than 5 mg/kg/day and the development of hepatocellular carcinomas was increased at doses greater than 50 mg/kg/day, with respective estimated exposures of 1- and 9-fold the AUC of the 40 mg clinical dose. Hepatocellular tumours, which were also observed in female mice at oral doses greater than 25 mg/kg/day (exposure similar to clinical exposure), may be associated with pantoprazole-induced increases in hepatic enzyme activity.

Treatment with pantoprazole at doses greater than 50 mg/kg/day (exposure approximately 9-fold clinical exposure) also increased the development of thyroid follicular cell adenomas in male and female rats. Several studies in rats were conducted to investigate the effect of pantoprazole on the thyroid, the results of which suggested that the effect may be secondary to the induction of enzymes in the liver.

In a more recent carcinogenicity study, Fischer rats were studied using lower oral doses (5, 15 and 50 mg/kg/day, 0.5-, 2- and 7-fold the clinical AUC, respectively). Gastric carcinoids were detected at all doses in females and at the 15 and 50 mg/kg doses in males, while none were detected in controls. No metastases of these carcinoids were detected. There was no increase in incidence of liver tumours. The dose of 15 mg/kg is seen to be the no-effect level for liver tumours in rodents.

Consideration of the possible mechanisms involved in the development of the above drug-related tumour types suggests that it is unlikely that there is any carcinogenic risk in humans at therapeutic dose levels of pantoprazole for short term treatment.

**6 PHARMACEUTICAL PARTICULARS**

**6.1 LIST OF EXCIPIENTS**

SALPRAZ tablets contain mannitol, sodium carbonate, sodium starch glycollate, crospovidone, colloidal anhydrous silica, calcium stearate, hypromellose, Macrogol 6000, sodium hydroxide, Eudragit L30-D55 (3700) and Opadry AMB Aqueous Moisture Barrier Coating System 80W52172 Yellow (106688).

SALPRAZ tablets are gluten free.

**6.2 INCOMPATIBILITIES**

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

**6.3 SHELF LIFE**
In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE
Store below 30°C.

6.5 NATURE AND CONTENTS OF CONTAINER
Container type: Al/Al blister packs
Pack sizes: 5, 14, 15, 28, 30, 50, 56, 60, 100 and 140 tablets
Some strengths, pack sizes and/or pack types may not be marketed.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL
In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES
Pantoprazole is a substituted benzimidazole which inhibits basal and stimulated gastric secretion. It is a white to off white crystalline powder. Freely soluble in water and in ethanol (96 per cent), practically insoluble in hexane. Solubility is low at neutral pH and increases with increasing pH.

Chemical Structure

Chemical name: Sodium-5-(difluoromethoxy)-2-[(RS)-[(3,4-Dimethoxypyridin-2-yl)methyl]sulphanyl]benzimidazol-1-ide sesquihydrate
Molecular formula: C_{16}H_{14}F_{2}N_{3}Na_{0.5}S 1½ H_{2}O
Molecular weight: 432.4 (sodium salt x 1.5 H_{2}O)

CAS Number
164579-32-2

7 MEDICINE SCHEDULE (POISONS STANDARD)
S4 (Prescription Only Medicine)

8 SPONSOR
Alphapharm Pty Limited
Level 1, 30 The Bond
30 – 34 Hickson Road
Millers Point NSW 2000
ABN 93 002 359 739
## Summary Table of Changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of New Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Update to comply with IHIN, TGO 91 and minor editorial changes</td>
</tr>
<tr>
<td>4.8</td>
<td>Addition of rebound acid hypersecretion</td>
</tr>
</tbody>
</table>